Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease: Is the Field Ready for Precision Prescribing?
Cheedy Jaja, Wally R SmithAbstract
Background
Pain is the leading cause of morbidity and health care utilization in sickle cell disease (SCD). Opioids remain central to management, but marked interpatient variability in efficacy and toxicity complicates treatment and may contribute to undertreatment, adverse effects, and inconsistent outcomes. Pharmacogenomics offers a potential precision-medicine strategy for opioid selection in SCD, particularly for agents influenced by CYP2D6-mediated metabolism.
Methods
We conducted a narrative review of the state of the science over the past 5 years regarding pharmacogenomics and opioid prescribing in SCD. The review synthesized recent literature on SCD pain phenotypes, opioid-related pharmacogenes, prescribing guidance, and early implementation studies, with an emphasis on CYP2D6-dependent opioids, including codeine and tramadol.
Results
CYP2D6 emerges as the most clinically actionable pharmacogenetic target for opioid prescribing in SCD. Reduced CYP2D6 activity may impair the conversion of codeine and tramadol to active metabolites, contributing to poor analgesic response, whereas ultrarapid metabolism may increase exposure and toxicity risk. Over the past 5 years, the field has progressed from association studies to early clinical implementation, including genotype-guided prescribing, clinical decision support, and provider education. Available data suggest that a substantial subset of patients with SCD carries actionable CYP2D6 phenotypes, supporting the clinical relevance of genotype-informed opioid selection. However, pharmacogenomic results alone are insufficient and must be interpreted in the context of pain phenotype, organ function, drug-drug interactions, and psychosocial factors.
Conclusions
Pharmacogenomics is becoming an actionable component of precision pain management in SCD. The strongest current evidence supports targeted CYP2D6-informed prescribing when codeine or tramadol are being considered. Broader pharmacogenomic testing for all opioid decisions is not yet justified, but the field is sufficiently mature to support prospective implementation in hematology care. Integrating CYP2D6-guided prescribing into SCD practice now represents a realistic next step toward safer and more effective pain treatment.
Additional Information
Research Region of Origin UNITED STATES